KPV
Lys-Pro-Val
KPV is the Lys-Pro-Val tripeptide investigated in inflammation models. Its published effects are tied to particular cells, transport systems and experimental conditions.
Reviewed September 2026
- Residues
- 3. calculated: Count of residues in the stored canonical reference sequence; terminal groups are not extra residues.
- Average mass
- 342.43 Da. calculated: Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded.
- pI
- 8.75 (theoretical). calculated: Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation.
Primary structure
Sequence
Peptide. Sequence describes the reference peptide, not a tested supplier lot.
Calculated properties
| Formula | C16H30N4O4 |
|---|---|
| Monoisotopic mass | 342.2267 Da |
| Extinction coefficient at 280 nm | None (no Tyr or Trp) |
| A280 at 1 mg/mL | Not measurable |
| Residues | 3 |
| Average mass | 342.43 Da |
| pI | 8.75 (theoretical) |
| Aliases | Lys-Pro-Val |
|---|---|
| Sequence | KPV |
| Research area | Immune |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Calculation scope: the stored canonical amino-acid sequence with free N- and C-termini, no other modifications or counterions. This specifies a reference form, not the chemical form or identity of a sold lot.
- Residues: 3 (calculated). Count of residues in the stored canonical reference sequence; terminal groups are not extra residues. Residues source 1
- Average mass: 342.43 Da (calculated). Calculated average neutral molecular mass of the unmodified free-terminal sequence, including one terminal water. Not monoisotopic mass; salts, counterions and solvates excluded. Average mass source 1 Average mass source 2 Average mass source 3
- pI: 8.75 (theoretical) (calculated). Theoretical Bjellqvist/Biopython charge-model pI for the stated free-terminal, unmodified sequence (pH search 0–14). Model-dependent, not measured pI or formulation pH; not applicable to an unspecified amidated, acetylated or salt preparation. pI source 1 pI source 2
Reference scope and linked records
Reference type: Peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: KPV. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About KPV
Identity and context
A sequence of three residues is chemically compact, but does not remove the need to identify terminal groups and chemical form. KPV should not be treated as synonymous with the full alpha-melanocyte-stimulating hormone from which this motif is discussed.
Reference classification
Peptide. The linked catalogue product is KPV. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Confirm the Lys-Pro-Val identity and terminal chemistry. Match transporter expression and model conditions when interpreting a cellular response; a peptide name alone does not specify the experimental system.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | A primary study tested uptake through the PepT1 transporter in intestinal epithelial and immune cells and examined two chemically induced mouse colitis models. The investigators measured inflammatory signalling and cytokine-related endpoints. This provides a mechanistic basis for further experiments. | Source context |
| What cannot be inferred | The cited work does not establish treatment efficacy for inflammatory bowel disease in humans. It also does not establish efficacy of a blend merely because KPV is listed among its ingredients. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.